"Pyrimidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
| Descriptor ID |
D011743
|
| MeSH Number(s) |
D03.383.742
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrimidines".
Below are MeSH descriptors whose meaning is more specific than "Pyrimidines".
This graph shows the total number of publications written about "Pyrimidines" by people in this website by year, and whether "Pyrimidines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1998 | 2 | 0 | 2 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 3 | 3 |
| 2003 | 5 | 1 | 6 |
| 2004 | 6 | 3 | 9 |
| 2005 | 3 | 1 | 4 |
| 2006 | 5 | 2 | 7 |
| 2007 | 6 | 4 | 10 |
| 2008 | 9 | 1 | 10 |
| 2009 | 4 | 1 | 5 |
| 2010 | 7 | 2 | 9 |
| 2011 | 11 | 10 | 21 |
| 2012 | 4 | 5 | 9 |
| 2013 | 11 | 12 | 23 |
| 2014 | 10 | 5 | 15 |
| 2015 | 8 | 7 | 15 |
| 2016 | 19 | 6 | 25 |
| 2017 | 9 | 14 | 23 |
| 2018 | 16 | 9 | 25 |
| 2019 | 5 | 9 | 14 |
| 2020 | 6 | 10 | 16 |
| 2021 | 6 | 7 | 13 |
| 2022 | 1 | 11 | 12 |
| 2023 | 2 | 13 | 15 |
| 2024 | 8 | 11 | 19 |
| 2025 | 7 | 13 | 20 |
| 2026 | 9 | 5 | 14 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyrimidines" by people in Profiles.
-
Development of a structurally distinct TopBP1 inhibitor that enhances PARP blockade and reverses osimertinib resistance. Sci Adv. 2026 Aug 07; 12(32):eaeg1996.
-
Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson's disease (TEMPO-2): a phase 3, randomised, placebo-controlled, double-blind trial. Lancet Neurol. 2026 Aug; 25(8):721-730.
-
Evolution of tumor subclones and T-cell dynamics underlie variable ibrutinib responses in Waldenstr?m macroglobulinemia. Blood. 2026 05 14; 147(20):2298-2314.
-
Dissecting Pirtobrutinib Resistance in Mantle Cell Lymphoma Through Single-Cell Multi-Omics. Am J Hematol. 2026 Jul; 101(7):1632-1649.
-
Venetoclax or Pirtobrutinib in Relapsed/Refractory Waldenstr?m Macroglobulinemia: Clinical and Molecular Predictors and Sequencing Implications. Am J Hematol. 2026 May; 101(5):1045-1055.
-
Summary of Research: Risdiplam Treatment Following Onasemnogene Abeparvovec in Individuals with Spinal Muscular Atrophy: A Multicenter Case Series. Adv Ther. 2026 Apr; 43(4):1380-1383.
-
The 201 Trial: a placebo-controlled randomized phase 2 study of safety and tolerance of the c-Abl kinase inhibitor risvodetinib in untreated Parkinson's disease. Nat Aging. 2026 Mar; 6(3):626-635.
-
Nilotinib-Induced Retinal Artery Thrombosis in a Patient With Chronic Myeloid Leukaemia: A Rare Case. Cancer Rep (Hoboken). 2026 02; 9(2):e70501.
-
DHODH links mitochondrial bioenergetics, one-carbon metabolism, and DNA repair to sustain aggressive prostate adenocarcinoma. Cell Commun Signal. 2026 Jan 29; 24(1).
-
Evaluating Photochemical Interactions Between Rose Bengal Photodynamic Antimicrobial Therapy and Topical Antifungals in Fungal Keratitis Isolates. Invest Ophthalmol Vis Sci. 2026 01 05; 67(1):11.